Certified by Founder Lodge
Nextech Invest
Switzerland - Zurich
INVESTOR
1 Disclosed Funding Rounds $122,000,000
51 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Nextech is a global, cancer therapeutics-focused venture capital firm headquartered in Zurich, Switzerland. We focus almost exclusively on oncology therapeutics, and on helping to drive value
| Company | Date | Round | Raised |
|---|---|---|---|
 IDRx |
August, 02 ,2022 | Series A | $122,000,000 |
 Mariana Oncology |
September, 08 ,2023 | Series B | $175,000,000 |
 Flare Therapeutics |
March, 23 ,2023 | Series B | $123,000,000 |
| Mariana Oncology |
September, 08 ,2023 | Series B | $175,000,000 |
 Atavistik Bio |
December, 26 ,2023 | Unknown | $40,000,000 |
 Alterome Therapeutics, Inc |
April, 09 ,2024 | Series B | $132,000,000 |
| Atavistik Bio |
December, 26 ,2023 | Unknown | $40,000,000 |
| IDRx |
August, 02 ,2022 | Series A | $122,000,000 |
 Delphia Therapeutics |
May, 07 ,2024 | Series A | $67,000,000 |
| Flare Therapeutics |
March, 23 ,2023 | Series B | $123,000,000 |
 Boundless Bio |
May, 17 ,2023 | Series C | $100,000,000 |
| Atavistik Bio |
December, 26 ,2023 | Unknown | $40,000,000 |
 FogPharma |
March, 05 ,2024 | Series E | $145,000,000 |
| Atavistik Bio |
December, 26 ,2023 | Unknown | $40,000,000 |
| Delphia Therapeutics |
May, 07 ,2024 | Series A | $67,000,000 |
| FogPharma |
March, 05 ,2024 | Series E | $145,000,000 |
| Boundless Bio |
May, 17 ,2023 | Series C | $100,000,000 |
 Scorpion Therapeutics |
July, 17 ,2024 | Series C | $150,000,000 |
| FogPharma |
March, 05 ,2024 | Series E | $145,000,000 |
| Mariana Oncology |
September, 08 ,2023 | Series B | $175,000,000 |
| FogPharma |
March, 05 ,2024 | Series E | $145,000,000 |
| Alterome Therapeutics, Inc |
April, 09 ,2024 | Series B | $132,000,000 |
| Scorpion Therapeutics |
July, 17 ,2024 | Series C | $150,000,000 |
| Alterome Therapeutics, Inc |
April, 09 ,2024 | Series B | $132,000,000 |
| Mariana Oncology |
September, 08 ,2023 | Series B | $175,000,000 |
| Delphia Therapeutics |
May, 07 ,2024 | Series A | $67,000,000 |
| Alterome Therapeutics, Inc |
April, 09 ,2024 | Series B | $132,000,000 |
| Atavistik Bio |
December, 26 ,2023 | Unknown | $40,000,000 |
| Alterome Therapeutics, Inc |
April, 09 ,2024 | Series B | $132,000,000 |
| Scorpion Therapeutics |
July, 17 ,2024 | Series C | $150,000,000 |
| Delphia Therapeutics |
May, 07 ,2024 | Series A | $67,000,000 |
| Delphia Therapeutics |
May, 07 ,2024 | Series A | $67,000,000 |
| Atavistik Bio |
December, 26 ,2023 | Unknown | $40,000,000 |
 Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
| Scorpion Therapeutics |
July, 17 ,2024 | Series C | $150,000,000 |
| FogPharma |
March, 05 ,2024 | Series E | $145,000,000 |
| Delphia Therapeutics |
May, 07 ,2024 | Series A | $67,000,000 |
| Scorpion Therapeutics |
July, 17 ,2024 | Series C | $150,000,000 |
| Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
| Alterome Therapeutics, Inc |
April, 09 ,2024 | Series B | $132,000,000 |
| FogPharma |
March, 05 ,2024 | Series E | $145,000,000 |
| Delphia Therapeutics |
May, 07 ,2024 | Series A | $67,000,000 |
| Scorpion Therapeutics |
July, 17 ,2024 | Series C | $150,000,000 |
| Scorpion Therapeutics |
July, 17 ,2024 | Series C | $150,000,000 |
| Alterome Therapeutics, Inc |
April, 09 ,2024 | Series B | $132,000,000 |
| Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
| Delphia Therapeutics |
May, 07 ,2024 | Series A | $67,000,000 |
 Tubulis GmbH |
October, 16 ,2025 | Series C | $359,197,300 |
| Scorpion Therapeutics |
July, 17 ,2024 | Series C | $150,000,000 |
| Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
| Tubulis GmbH |
October, 16 ,2025 | Series C | $359,197,300 |
Cherry Ventures
Blue Bear Capital
Slow Ventures
Climate Capital
Eniac Ventures
Sizable Energy | $8,000,000 | (Oct 24, 2025)
Sumble | $38,500,000 | (Oct 24, 2025)
Syntracts | $5,300,000 | (Oct 24, 2025)
Cybrid | $10,000,000 | (Oct 24, 2025)
Elevara Medicines | $70,000,000 | (Oct 24, 2025)
